Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CBT 005

Next Previous
X
Search
Drug Profile

CBT 005

Alternative Names: CBT-005

Latest Information Update: 03 Sep 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cloudbreak therapeutics
  • Class Antibodies; Drug conjugates; Eye disorder therapies; Immunoconjugates
  • Mechanism of Action Fibroblast growth factor receptor antagonists; Platelet-derived growth factor receptor antagonists; Vascular endothelial growth factor A inhibitors; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists; Vascular endothelial growth factor receptor-3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Wet age-related macular degeneration

Most Recent Events

  • 27 Aug 2021 Cloudbreak therapeutics has patent protection for ophthalmic drug candidates (Cloudbreak Therapeutics website, August 2021)
  • 26 Aug 2021 Preclinical trials in Wet age-related macular degeneration in USA (Intravitreous) (Cloudbreak Therapeutics website, August 2021)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top